BPC-157 (PL-10, PLD-116, PL 14736) in IBD clinical trials is supported by comprehensive animal evidence: healing across multiple gut inflammation models, cytoprotection, anti-inflammation, and NO/prostaglandin modulation.
Key findingBPC-157 (Pliva clinical trial designations: PL-10, PLD-116, PL 14736) for IBD is supported by extensive animal data: heals colitis/esophagitis/gastric
What the researchers found
BPC-157 (Pliva clinical trial designations: PL-10, PLD-116, PL 14736) for IBD is supported by extensive animal data: heals colitis/esophagitis/gastric lesions, provides cytoprotection, reduces inflammation through NO and prostaglandin pathways, and maintains gut integrity across multiple models.
Why it matters
Relevant for bpc-157, gut-healing.
How the study worked
animal-study study on bpc-157, gut-healing.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.
Inflammopharmacology, 14(5-6), 214-21
Citation
Sikiric, P; Seiwerth, S; Brcic, L; Blagaic, A B; Zoricic, I; Sever, M; Klicek, R; Radic, B; Keller, N; Sipos, K; Jakir, A; Udovicic, M; Tonkic, A; Kokic, N; Turkovic, B; Mise, S; Anic, T. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.. Inflammopharmacology, 14(5-6), 214-21.